[1]安 钰,李 扬,王 海,等.胃癌患者血清PG、G-17、IL-6、IL-23、IL-17、TNF-α的检测价值[J].医学信息,2024,37(16):64-67.[doi:10.3969/j.issn.1006-1959.2024.16.013]
　AN Yu,LI Yang,WANG Hai,et al.Detection Value of Serum PG, G-17, IL-6, IL-23, IL-17 and TNF-α in Patients with Gastric Cancer[J].Journal of Medical Information,2024,37(16):64-67.[doi:10.3969/j.issn.1006-1959.2024.16.013]
点击复制

胃癌患者血清PG、G-17、IL-6、IL-23、IL-17、TNF-α的检测价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年16期
页码:
64-67
栏目:
论著
出版日期:
2024-08-15

文章信息/Info

Title:
Detection Value of Serum PG, G-17, IL-6, IL-23, IL-17 and TNF-α in Patients with Gastric Cancer
文章编号:
1006-1959（2024）16-0064-04
作者:
安 钰1; 李 扬2; 王 海1; 苏成东1; 高瑞萍1; 于晓兵1
宁夏回族自治区人民医院消化内科1，内镜中心2，宁夏 银川 750021
Author(s):
AN Yu1; LI Yang2; WANG Hai1; SU Cheng-dong1; GAO Rui-ping1; YU Xiao-bing1
Department of Digestive Diseases1,Department of Endoscopy Center2,People’s Hospital of Ningxia Hui Autonomous Region,Yinchuan 750021,Ningxia,China
关键词:
胃癌; PGⅠ; PGⅡ; G-17 IL; TNF-α
Keywords:
Gastric cancer; PGⅠ; PGⅡ; G-17 IL; TNF-α
分类号:
R735.2；R446.11
DOI:
10.3969/j.issn.1006-1959.2024.16.013
文献标志码:
A
摘要:
目的 分析胃癌患者血清胃蛋白酶原（PG，PGⅠ、PGⅡ）、胃泌素-17（G-17）、白介素（IL）-6、IL-23、IL-17、肿瘤坏死因子-α（TNF-α）的变化及联合检测价值。方法 选择2022年1月-2023年2月于我院就诊的胃癌患者122例为观察组，100例体检健康受试者为对照组，进行平行对照研究。PGⅠ、PGⅡ、G-17采用双抗体夹心免疫检测法，IL-6、IL-23、IL-17、TNF-α采用酶联免疫吸附试验（ELISA）检测。比较两组血清PGⅠ、PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平，观察组TNM肿瘤分期Ⅰ~Ⅱ期与Ⅲ~Ⅳ期各血清指标的差异。采用受试者工作特征曲线（ROC曲线）分析各血清指标联合检测对胃癌进展（Ⅲ~Ⅳ期）的预测价值。结果 观察组血清PGⅠ低于对照组，血清PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平均高于对照组（P＜0.05）；胃癌患者TNMⅠ~Ⅱ期血清PGⅠ高于TNM Ⅲ~Ⅳ期，血清PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平均低于TNM Ⅲ~Ⅳ期（P＜0.05）。单项血清检查中PGⅠ预测胃癌进展AUC较高，为0.976，但各血清指标联合检测预测胃癌进展（Ⅲ~Ⅳ期）的AUC更高，为0.984，特异度98.90%，灵敏度92.60%。结论 胃癌患者PGⅡ、G-17、IL-6、IL-23、IL-17、TNF-α水平呈现高表达，PGⅠ水平呈低表达，不同TNM分期差异显著，可预测胃癌进展，以联合检测效用最高。
Abstract:
Objective To analyze the changes and combined detection value of serum pepsinogen (PG, PGⅠ, PGⅡ), gastrin-17 (G-17), interleukin (IL)-6, IL-23, IL-17 and tumor necrosis factor-α (TNF-α) in patients with gastric cancer.Methods A total of 122 patients with gastric cancer who were treated in our hospital from January 2022 to February 2023 were selected as the observation group, and 100 healthy subjects were selected as the control group for parallel control study. PGI, PGII and G-17 were detected by double antibody sandwich immunoassay, and IL-6, IL-23, IL-17 and TNF-α were detected by enzyme-linked immunosorbent assay (ELISA). The levels of serum PGⅠ, PGⅡ, G-17, IL-6, IL-23, IL-17 and TNF-α were compared between the two groups, and the differences of serum indexes between TNM stage Ⅰ-Ⅱ andstageⅢ-Ⅳ in the observation group were compared. The receiver operating characteristic curve (ROC curve) was used to analyze the predictive value of combined detection of serum indicators for gastric cancer progression (stage Ⅲ-Ⅳ).Results The serum PGI in the observation group was lower than that in the control group, and the levels of serum PGⅡ, G-17, IL-6, IL-23, IL-17 and TNF-α were higher than those in the control group (P<0.05). The levels of serum PGI in patients with gastric cancer at TNM stage Ⅰ-Ⅱ were higher than those at TNM stage Ⅲ-Ⅳ, and the levels of serum PGⅡ, G-17, IL-6, IL-23, IL-17 and TNF-α were lower than those at TNM stage Ⅲ-Ⅳ(P<0.05). In the single serum examination, the AUC of PGI in predicting the progression of gastric cancer was higher, which was 0.976, but the AUC of the combined detection of serum indexes in predicting the progression of gastric cancer (stage Ⅲ-Ⅳ) was higher, which was 0.984, the specificity was 98.90%, and the sensitivity was 92.60%.Conclusion The levels of PGⅡ, G-17, IL-6, IL-23, IL-17 and TNF-α in patients with gastric cancer are highly expressed, and the level of PGI is low. There are significant differences in different TNM stages, which can predict the progression of gastric cancer, and the combined detection has the highest effect.

参考文献/References:

[1]忻笑容,吴云林,陈平,等.胃癌608例临床及病理特征分析[J].诊断学理论与实践,2019,18(4):470-472.[2]熊建平,田艳涛.莘胃癌炎症相关预后评价体系的构建、优化与创新[J].中国医学前沿杂志(电子版),2022,14(12):11-14.[3]Karimi P,Islami F,Anandasabapathy S,et al.Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention[J].Cancer Epidemiol Biomarkers Prev,2014,23(5):700-713.[4]Han XL,Yi CL,Ma JD,et al.Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer[J].Lab Med,2022,53(1):71-77.[5]Zagari RM,Rabitti S,Greenwood DC,et al.Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis[J].Aliment Pharmacol Ther,2017,46(7):657-667.[6]吴开春.胃癌发生与幽门螺杆菌相关胃炎及癌前病变[J].肿瘤综合治疗电子杂志,2022,8(2):1-4.[7]余建洪,彭庆远,殷明刚.自贡地区表观健康成人血清PGⅠ、PGⅡ和PGR参考区间的建立[J].检验医学,2022,37(1):23-27.[8]亢晓春,陈美玲,王亚楠,等.血清PGⅠ、PGⅡ水平结合EUS术前诊断胃癌分期的价值[J].分子诊断与治疗杂志,2021,13(9):1533-1536.[9]史跃燕,林兰,顾益凤,等.血清CEA、CA19-9、CA72-4、G-17、PGⅠ、PGⅡ在胃癌中的表达及意义[J].检验医学与临床,2022,19(17):2305-2308,2313.[10]詹长欣,詹雪梅,俞桦.血清G-17、PGⅠ、PGⅡ联合HP阳性检测用于胃癌筛查的价值[J].现代消化及介入诊疗,2021,26(6):772-774,779.[11]胡维林,邓元河,尹小兵,等.血清PGⅠ、PGⅡ及胃泌素17水平的变化与老年胃癌患病的关系分析[J].中国实验诊断学,2021,25(11):1649-1652.[12]侯晶晶.胃癌患者外周血Th17细胞相关因子检测及其临床意义[J].现代诊断与治疗,2020,31(6):960-961.[13]易静,龚锦文,赵静,等.miR-71通过IL-23/Th17信号通路对人胃早癌肿瘤浸润免疫细胞的影响[J].实用医学杂志,2020,36(2):200-205.[14]徐宪辉.IL-23在胃癌侵袭转移中的作用及机制研究[D].重庆:陆军军医大学,2018.[15]禚娅,黄晋.胃癌患者外周血白细胞介素的检测价值[J].中国肿瘤临床与康复,2020,27(3):327-330.[16]蔡美霞.胃癌患者外周血白细胞介素-6(IL-6),白细胞介素-23(IL-23)和白细胞介素-17(IL-17)因子的检测价值[J].首都食品与医药,2022,29(14):32-34.[17]牟晓映,高美华,韩春华.胃癌患者外周血Th17细胞、血清IL-17、IL-6水平检测及临床意义[J].海南医学,2020,31(24):3155-3158.[18]李杰,陈国栋,曾莎莎,等.幽门螺杆菌Tipα蛋白的表达、纯化及对胃癌细胞增殖和迁移的影响[J].中国病原生物学杂志,2019,14(9):1024-1028.[19]唐军梅,张启芳,何思明,等.幽门螺杆菌Tipα对胃癌细胞顺铂敏感性的影响[J].重庆医学,2022,51(1):29-33,40.[20]曾莎莎,肖玲巧,唐瑶,等.幽门螺杆菌Tipα通过Wnt/β-catenin通路诱导胃癌细胞EMT[J].中南医学科学杂志,2020,48(6):618-623.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
　YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Journal of Medical Information,2018,31(16):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,31(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
　RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Journal of Medical Information,2018,31(16):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,31(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
　DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Journal of Medical Information,2018,31(16):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,31(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
　PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Journal of Medical Information,2018,31(16):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]李虹霞,刘伏山.慢性萎缩性胃炎的中西医治疗[J].医学信息,2022,35(11):29.[doi:10.3969/j.issn.1006-1959.2022.11.009]
　LI Hong-Xia,LIU Fu-shan.Treatment of Chronic Atrophic Gastritis with Traditional Chinese and Western Medicine[J].Journal of Medical Information,2022,35(16):29.[doi:10.3969/j.issn.1006-1959.2022.11.009]
[6]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(16):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[7]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,31(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
　LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Journal of Medical Information,2018,31(16):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[8]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,31(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
　MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Journal of Medical Information,2018,31(16):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[9]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,31(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
　ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Journal of Medical Information,2018,31(16):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
[10]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
　WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Journal of Medical Information,2018,31(16):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]

更新日期/Last Update: 1900-01-01